$1 Stocks to Watch: JSPR, FTEL, BYND, TOON Decemb
Post# of 36931
https://thestreetreports.com/1-stocks-to-watc...re-inside/
A surge of low-priced names is capturing trader attention as December 2025 opens, with several companies showing fresh catalysts, rising volume, or renewed investor interest. From biotech breakthroughs to entertainment-sector momentum, these $1 stocks are positioning themselves as year-end watchlist leaders.
Jasper Therapeutics Inc. (NASDAQ: JSPR) is one of December’s most active micro-cap biotechs after releasing encouraging preliminary data from its ETESIAN Study in allergic asthma. A single dose of briquilimab showed reductions in sputum eosinophils and improved lung function at 6 and 12 weeks. The company also completed its BEACON Study investigation, concluding that past variability stemmed from patient-selection issues, not the drug itself. Together, these updates have reignited investor interest and firmly positioned JSPR on this month’s high-watch list.
Fitell Corporation (NASDAQ: FTEL) is drawing heavy attention after reporting solid fiscal-year revenue growth and improved profitability while also approving a $3 million share-repurchase program. The company continues to expand its health and robotics initiatives through its 2F Robotics venture, backed by stablecoin-linked funding.
Kartoon Studios Inc. (NYSE: TOON) is emerging as one of the strongest sub-$1 entertainment stocks heading into year-end, posting double-digit revenue growth led by Mainframe Studios and a record October for Kartoon Channel!. The company strengthened its balance sheet with recent financing and is advancing major initiatives, including its new “STAN A.I.” animation technology. With rising operational momentum across multiple business lines, TOON is becoming a standout among December’s low-priced stocks giants in the industry Warner Bros. Discovery (NASDAQ: WBD) and Paramount Skydance Corporation (NASDAQ: PSKY)
My Size, Inc. (NASDAQ: MYSZ) Trading quietly around the $1 mark, My Size has not issued major new developments early this month. The stock often exhibits sharp low-float fluctuations on even modest retail interest, making it a name that traders monitor closely despite the absence of near-term catalysts.
Peraso Inc. (NASDAQ: PRSO) continues hovering just under the dollar level as the market awaits its next mmWave or fixed-wireless update. Earlier in the year, the company secured multiple design wins and new OEM volume orders—momentum that traders still view as potentially reactivating. While December has been quiet so far, PRSO remains capable of rapid price movement given its history and lean float.
Beyond Meat, Inc. (NASDAQ: BYND) remains in the mid-$1 range as the company continues navigating competitive pressures, rising production costs, and shifting consumer sentiment in the plant-based sector. Despite the absence of major new catalysts, BYND consistently attracts interest due to its recognizable brand and potential for sizable percentage swings at low share prices.
Aprea Therapeutics Inc. (NASDAQ: APRE) trades just above $1 as it continues pushing forward its precision-oncology programs targeting DNA-damage repair, p53 modulation, and other genetically driven cancer pathways. Although December has not brought new clinical updates, APRE remains on watch for biotech momentum traders looking for asymmetry within early-stage oncology development.
Power Metallic Mines (TSX-V: PNPN | OTCQB: PNPNF) reported one of its strongest drilling results to date, intercepting 4.40 meters of 12.18% Cu (14.34% CuEq) within a broader 20.40-meter interval grading 2.91% Cu (3.58% CuEq) at its Lion Zone during the summer drill program. The company also completed the extension of hole PN-24-064 to better define a large off-hole BHEM anomaly, reinforcing the potential scale of the system. Read Entire Release.
December Micro-Cap Setup: Momentum Rotates Back to the $1 Tier
With volatility returning and traders seeking year-end catalysts, the $1-stock category is once again in focus. This month’s lineup offers a clear division:
JSPR leading with clinical data momentum
FTEL gaining traction on revenue strength and share-repurchases
TOON standing out on operational growth and digital-media expansion
BYND maintaining brand-driven speculative interest
PNPN.V PRSO, APRE, PNPNF and MYSZ offering potential on any fresh news trigger
As December continues, these names may deliver high-velocity moves driven by news flow, sentiment, or sector rotation.